Alvotech is a biopharmaceutical company focused solely on the development and manufacture of biosimilar medicines for patients globally. Its purpose is to improve the health and quality of life of patients around the world by improving access to treatments for various diseases. The company's commercialized products incldue AVT02, AVT03, AVT04, AVT05, and AVT06. Its pipeline contains eight biosimilar candidates aimed at treating autoimmune disorders, eye disorders, osteoporosis, and cancer. Geographically, the company generates the majority of revenue from Europe, and the rest from the USA and the rest of the world.
Last trade$4.27
Day change-$0.135 (-3.06%)
Day range$4.25 – $4.64
Volume795,088
Market cap$1.57B
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
No ratio data was found for ALVO.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
No quarterly
income statement data was found for ALVO.
Recent news
Company coverage with links to the original publishers.
Alvotech reported a quarterly loss of $0.03 per share, significantly worse than the consensus estimate of $0.01 loss, representing a -200% earnings surprise. Revenue of $111.56 million also missed estimates by 18.62%. The stock has underperformed the S&P 500 by 14.8% year-to-date and carries a Zacks Rank #4 (Sell) rating due to unfavorable estimate revision trends.
Editas Medicine reported a quarterly loss of $0.15 per share, beating consensus estimates of $0.21 loss, with revenues of $10.37 million significantly exceeding expectations. The stock has gained 25.4% year-to-date, outperforming the S&P 500. However, the company holds a Zacks Rank #3 (Hold) rating with mixed estimate revisions, suggesting near-term performance in line with the market. Peer company Alvotech is expected to report results on November 11.
Alvotech is expected to report a quarterly loss of $0.01 per share with revenues of $137.09 million (up 20.4% YoY) on November 11, 2026. Despite a positive Earnings ESP of +250%, the stock's Zacks Rank #4 (Sell) rating makes it difficult to predict an earnings beat. The company has failed to beat consensus EPS estimates in the last four quarters, with the most recent quarter delivering an -83.33% surprise.
Alvotech, a global biotechnology company specializing in biosimilar medicines, will present at four international investor conferences in November 2026 across the UK, Norway, and Sweden. The company will participate in UBS's biotech conference in London, Jefferies' healthcare conference in London, DNB Carnegie's healthcare conference in Oslo, and SEB's healthcare conference in Stockholm. Live streams and recordings of these presentations will be available on the company's events page.
Alvotech, a global biotechnology company specializing in biosimilar medicines, announced that its management team will participate in four major investor conferences across Europe in November 2026, including presentations at UBS Global Biopharma Conference, Jefferies Global Healthcare Conference, DNB Carnegie Healthcare Conference, and SEB Healthcare Seminar. Live audio webcasts will be available on the company's website.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.